Canaccord Genuity Group Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price

Neurocrine Biosciences (NASDAQ:NBIX) had its target price upped by Canaccord Genuity Group from $164.00 to $200.00 in a research note published on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

NBIX has been the subject of a number of other reports. Weiss Ratings reissued a “hold (c+)” rating on shares of Neurocrine Biosciences in a research note on Thursday, January 22nd. Truist Financial dropped their price target on Neurocrine Biosciences from $169.00 to $140.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. UBS Group dropped their price target on Neurocrine Biosciences from $188.00 to $178.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. Morgan Stanley reissued an “equal weight” rating and set a $175.00 price target (up from $173.00) on shares of Neurocrine Biosciences in a research note on Thursday, January 8th. Finally, Stifel Nicolaus increased their price target on Neurocrine Biosciences from $183.00 to $188.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $180.70.

Neurocrine Biosciences Stock Down 1.2%

NASDAQ NBIX opened at $130.90 on Tuesday. The firm has a market cap of $13.14 billion, a price-to-earnings ratio of 28.09, a price-to-earnings-growth ratio of 0.69 and a beta of 0.35. The business has a 50-day moving average price of $131.46 and a 200-day moving average price of $138.91. Neurocrine Biosciences has a twelve month low of $84.23 and a twelve month high of $160.18.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Wednesday, February 11th. The company reported $1.88 earnings per share for the quarter, missing analysts’ consensus estimates of $2.36 by ($0.48). Neurocrine Biosciences had a return on equity of 16.48% and a net margin of 16.73%.The business had revenue of $805.50 million during the quarter, compared to the consensus estimate of $804.21 million. During the same period last year, the company earned $1.69 EPS. The business’s revenue was up 28.3% on a year-over-year basis. Research analysts expect that Neurocrine Biosciences will post 4.28 EPS for the current fiscal year.

Insider Activity

In other news, CEO Kyle Gano sold 36,400 shares of the firm’s stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $132.70, for a total value of $4,830,280.00. Following the completion of the sale, the chief executive officer directly owned 140,407 shares of the company’s stock, valued at $18,632,008.90. This trade represents a 20.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Neurocrine Biosciences

Several institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. lifted its stake in shares of Neurocrine Biosciences by 11.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,730,152 shares of the company’s stock valued at $664,019,000 after purchasing an additional 468,405 shares during the last quarter. AQR Capital Management LLC lifted its stake in shares of Neurocrine Biosciences by 18.0% in the 4th quarter. AQR Capital Management LLC now owns 3,271,706 shares of the company’s stock valued at $462,652,000 after purchasing an additional 498,058 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Neurocrine Biosciences by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 2,059,282 shares of the company’s stock worth $291,342,000 after buying an additional 34,457 shares during the period. Los Angeles Capital Management LLC raised its holdings in shares of Neurocrine Biosciences by 7.4% in the fourth quarter. Los Angeles Capital Management LLC now owns 1,291,278 shares of the company’s stock worth $178,248,000 after buying an additional 88,522 shares during the period. Finally, Northern Trust Corp raised its holdings in shares of Neurocrine Biosciences by 31.9% in the fourth quarter. Northern Trust Corp now owns 1,221,184 shares of the company’s stock worth $173,201,000 after buying an additional 295,470 shares during the period. 92.59% of the stock is owned by institutional investors.

Trending Headlines about Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Acquisition materially expands Neurocrine’s commercial footprint — adds VYKAT XR (first‑and‑only FDA‑approved therapy for hyperphagia in Prader‑Willi syndrome) and pushes the company into endocrinology/rare metabolic diseases, creating a multi‑product commercial platform alongside INGREZZA and CRENESSITY. Neurocrine Grows in Endocrinology, Rare Disease with $2.9B Soleno Buyout
• Positive Sentiment: Analysts reacted by lifting price targets and reiterating buys — multiple firms (Citigroup, Canaccord, HC Wainwright, BofA, Needham, Wedbush) raised targets substantially, signaling upside to consensus estimates and investor confidence in the deal’s revenue potential. Vykat XR Acquisition Unlocks Diversified Growth — TipRanks
• Neutral Sentiment: Market validated Soleno’s value — SLNO shares jumped sharply on the deal, confirming the premium paid by Neurocrine and market willingness to pay for VYKAT XR’s orphan indication. This supports deal rationale but doesn’t guarantee NBIX near‑term earnings upside. Soleno Therapeutics Soars 32% on $2.9B Merger
• Neutral Sentiment: Soleno voluntarily withdrew its European marketing application for VYKAT XR ahead of the takeover — Neurocrine says it will prioritize the U.S. launch. That could accelerate U.S. commercialization focus but delays/forgoes near‑term EU revenue. Soleno withdraws EU rare disease drug application — Reuters
• Negative Sentiment: Shares dropped on deal announcement — investors appear concerned about the price tag ($2.9B cash), near‑term dilution to capital flexibility or execution risks integrating a new therapeutic area while Neurocrine’s pipeline faces a near‑term lull. This immediate negative reaction drove today’s decline. This Pharma Stock Is Surging 40% — Barron’s
• Negative Sentiment: Some analysts caution on execution and orphan market risks — at least one firm (BMO) kept a Hold, highlighting integration and long‑term execution questions that could cap near‑term multiple expansion. Balanced View on Neurocrine — TipRanks

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.